Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.55
+0.88501.37%
Volume:643.60K
Turnover:42.07M
Market Cap:12.67B
PE:172.96
High:66.30
Open:65.92
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.00
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.00
PE(LYR):36.42

Loading ...

BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live
·
May 18

Biomarin Pharmaceutical Shares Down 1% After Genetic Disease Therapy Shows Mixed Results in Late-Stage Study

THOMSON REUTERS
·
May 18

BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial

TIPRANKS
·
May 18

BioMarin's genetic disease therapy shows mixed results in late-stage study

Reuters
·
May 18

Biomarin Pharmaceutical Inc - Energy 3 Study Meets 1 of 2 Co-Primary Endpoints in Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Generally Well-Tolerated With No New Safety Signals Reported

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Improvement in Radiagraphic Global Impression of Change Scores in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Provides Update on Phase 3 Trial for Bmn 401 in Children Aged 1-12 With Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Shows Significant Increase in Plasma Inorganic Pyrophosphate in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Evaluating Data to Determine Next Steps for Bmn 401

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Positive Trends in Secondary Endpoints Including Rickets Severity Score and Growth Z-Score

THOMSON REUTERS
·
May 18

BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors

TIPRANKS
·
May 15

Zura Bio appoints Muzammil Mustufa chief business officer

Reuters
·
May 13

BioMarin EVP, Chief R&D Officer Gregory R. Friberg disposes 3,281 shares for $176,666.85

Reuters
·
May 12

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 08

Guggenheim Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 06

U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group

Reuters
·
May 06

Stock Track | BioMarin Pharmaceutical Plummets 5.01% Intraday on Lowered Earnings Outlook and Analyst Price Target Cuts

Stock Track
·
May 06

BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says

MT Newswires Live
·
May 06

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

MT Newswires Live
·
May 05